Patents by Inventor Sandor Batkai

Sandor Batkai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of heart failure in human subjects
    Patent number: 12630822
    Abstract: The present invention refers to an oligonucleotide, which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders of a human subject.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: May 19, 2026
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Thum, Claudia Ulbrich, Wilfried Hauke, Steffen Rump, Sandor Batkai
  • Compound for treatment of heart failure
    Patent number: 12600964
    Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: April 14, 2026
    Assignee: Medizinische Hochschule Hannover
    Inventors: Thomas Thum, Sandor Batkai, Ariana Foinquinos
  • TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS
    Publication number: 20220243204
    Abstract: The present invention refers to an oligonucleotide, which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders of a human subject.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 4, 2022
    Inventors: Thomas Thum, Claudia Ulbrich, Wilfried Hauke, Steffen Rump, Sandor Batkai
  • Compound for treatment of heart failure
    Publication number: 20220162597
    Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
    Type: Application
    Filed: November 17, 2021
    Publication date: May 26, 2022
    Inventors: Thomas Thum, Sandor Batkai, Ariana Foinquinos
  • Compound for treatment of heart failure
    Patent number: 11208651
    Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: December 28, 2021
    Assignee: Medizinische Hochschule Hannover
    Inventors: Thomas Thum, Sandor Batkai, Ariana Foinquinos
  • Improved Compound for Treatment of Heart Failure
    Publication number: 20210180054
    Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 17, 2021
    Inventors: Thomas Thum, Sandor Batkai, Ariana Foinquinos